AMARILLO, Texas--(BUSINESS WIRE)--Amarillo Biosciences, Inc. (ABI) (OTCBB:AMAR) today announced that it has filed a patent application with the U.S. Patent and Trademark Office with claims to methods of treating chronic coughing by administering interferon orally to diminish cough duration, frequency and intensity (now published as US Patent Application Publication No. US 2007/0237723). Although the examples in the patent application described a method of treating idiopathic pulmonary fibrosis and Sjogren’s syndrome, it is claimed that interferon will reduce coughing in many disease conditions, including chronic obstructive pulmonary disease (COPD).
